Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients

References

• Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013 Feb;68(2):250–256. PubMed PMID: 23099850.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006 Dec;80(6):668–681. PubMed PMID: 17178267.
   PubMed Web of Science ®Google Scholar
• Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):473–485. PubMed PMID: 16863456.
   PubMedGoogle Scholar
• Crauwels HM, van Heeswijk RPG, Vandevoorde A, et al. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. J Clin Pharmacol. 2014 Feb;54(2):133–140. PubMed PMID: 24203510.
   PubMed Web of Science ®Google Scholar
• Bart G, Lenz S, Rj S, et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014 Dec;1(145):185–193. PubMed PMID: 25456329; PubMed Central PMCID: PMCPMC4254688.
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001 Mar;51(3):213–217. PubMed PMID: 11298066; PubMed Central PMCID: PMCPMC2015032.
   PubMed Web of Science ®Google Scholar
• Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Nov;48(11):4148–4153. PubMed PMID: 15504834; PubMed Central PMCID: PMCPMC525438.
   PubMed Web of Science ®Google Scholar
• Crauwels HM, van Heeswijk RP, Buelens A, et al. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol. 2013 Aug;53(8):834–840. PubMed PMID: 23720136.
   PubMed Web of Science ®Google Scholar
• van Heeswijk R, Verboven P, Vandevoorde A, et al. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother. 2013 May;57(5):2304–2309. PubMed PMID: 23478952; PubMed Central PMCID: PMCPMC3632951.
   PubMed Web of Science ®Google Scholar
• Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol. 2004 Aug;58(2):156–162. PubMed PMID: 15255797; PubMed Central PMCID: PMCPMC1884589.
   PubMed Web of Science ®Google Scholar
• Hanna J, Foster DJ, Salter A, et al. Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br J Clin Pharmacol. 2005 Oct;60(4):404–413. PubMed PMID: 16187972; PubMed Central PMCID: PMCPMC1884832.
   PubMed Web of Science ®Google Scholar
• Kharasch ED. Current Concepts in Methadone Metabolism and Transport. Clin Pharmacol Drug Dev. 2017 Mar;6(2):125–134. PubMed PMID: 28263461.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Regina KJ, Blood J, et al. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015 Nov;123(5):1142–1153. PubMed PMID: 26389554; PubMed Central PMCID: PMCPMC4667947.
   PubMedGoogle Scholar
• Hughes CA, Robinson L, Tseng A, et al. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009 Oct;10(15):2445–2466. PubMed PMID: 19678794.
   PubMed Web of Science ®Google Scholar
• Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013 Apr-Jun;15(2):87–101. PubMed PMID: 23681436.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Reinhard R, Schnaidt S, et al. Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. J Antimicrob Chemother. 2016 Aug;71(8):2241–2247. PubMed PMID: 27141088.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shi CX, McGoogan JM, et al. Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ. 2013 Feb 1;91(2):93–101. PubMed PMID: 23554522; PubMed Central PMCID: PMCPMC3605005.
   PubMed Web of Science ®Google Scholar
• Yang HC, Chu SK, Huang CL, et al. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. PLoS Genet. 2016 Mar;12(3):e1005910. PubMed PMID: 27010727; PubMed Central PMCID: PMCPMC4806848.
   PubMed Web of Science ®Google Scholar
• Diong SH, Mohd Yusoff NS, Sim MS, et al. Quantitation of methadone and metabolite in patients under maintenance treatment. J Anal Toxicol. 2014 Nov-Dec;38(9):660–666. PubMed PMID: 25106416.
   PubMed Web of Science ®Google Scholar
• Peng S, Jiang H, Du J, et al. Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first drug use were associated with outcomes of methadone maintenance treatment. Front Genet. 2018;9:450. PubMed PMID: 30420869; PubMed Central PMCID: PMCPMC6216325.
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12(2):109–124. PubMed PMID: 18422375.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Hoffer C, et al. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 2012 Feb;116(2):432–447. PubMed PMID: 22273859; PubMed Central PMCID: PMCPMC3586934.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. Drug Metab Dispos. 2013 Dec;41(12):2166–2174. PubMed PMID: 24067429; PubMed Central PMCID: PMCPMC3834136.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Whittington D, et al. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009 May 1;101(3):158–168. PubMed PMID: 19232844; PubMed Central PMCID: PMCPMC3582041.
   PubMed Web of Science ®Google Scholar
• Dennis BB, Bawor M, Thabane L, et al. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114. PubMed PMID: 24489693; PubMed Central PMCID: PMCPMC3906028.
   PubMed Web of Science ®Google Scholar
• Levran O, Peles E, Hamon S, et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013 Jul;18(4):709–716. PubMed PMID: 21790905; PubMed Central PMCID: PMCPMC3735354.
   PubMed Web of Science ®Google Scholar
• Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484–487. PubMed PMID: 23428312.
   PubMed Web of Science ®Google Scholar